珍寶島(603567.SH):與浙江震元簽訂戰略合作框架協議
格隆匯7月1日丨珍寶島(603567.SH)公佈,公司與浙江震元股份有限公司(“浙江震元”)簽訂了《戰略合作框架協議》,雙方擬在商業渠道合作、院內製劑研發、藥材交易及資本股權方面進行合作,將圍繞中醫藥產業共同探討、協同發展。
雙方在中醫藥發展方面具備良好的合作基礎,並達成合作共識。對接國家中醫藥產業創新發展的新政策,珍寶島在中藥全品類產品、院內製劑及中藥材貿易等方面具備優勢;浙江震元是越醫文化具有代表性的傳承基地,在紹興以及浙江省、長三角地區具備廣泛影響力;雙方對共同推進中醫藥發展進行合作,在營銷、研發及投資等方面達成共識。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.